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ABSTRACT
Background.Current guidelines advise that rituximab or cyclo-
phosphamide should be used for the treatment of organ-
threatening disease in anti-neutrophil cytoplasm antibody
(ANCA)-associated vasculitis (AAV), although few studies
have examined the efﬁcacy and safety of these agents in
combination.
Methods. We conducted a single-centre cohort study of 66
patients treated with a combination of oral corticosteroids, rit-
uximab and low-dose pulsed intravenous cyclophosphamide
followed by a maintenance regimen of azathioprine and tapered
steroid for the treatment of biopsy-proven renal involvement in
AAV. Patients were followed for a median of 56months. Case–
control analysis with 198 propensity-matched cases from
European Vasculitis Study Group (EUVAS) trials compared
long-term differences in relapse-free, renal and patient survival.
Results. At entry, the median Birmingham Vasculitis Activity
Score (BVAS) was 19 and estimated glomerular ﬁltration rate
was 25mL/min. Cumulative doses of rituximab, cyclophospha-
mide and corticosteroids were 2, 3 and 4.2 g, respectively, at 6
months. A total of 94% of patients achieved disease remission
by 6 months (BVAS< 0) and patient and renal survival were 84
and 95%, respectively, at 5 years. A total of 84% achieved
ANCA-negative status and 57% remained B cell deplete at 2
years, which was associated with low rates of major relapse
(15% at 5 years). The serious infection rate during long-term
follow-up was 1.24 per 10 patient-years. Treatment with this
regimen was associated with a reduced risk of death {hazard
ratio [HR] 0.29 [95% conﬁdence interval (CI) 0.125–0.675],
P¼ 0.004}, progression to end-stage renal disease (ESRD) [HR
0.20 (95% CI 0.06–0.65), P¼ 0.007] and relapse [HR 0.49 (95%
CI 0.25–0.97), P¼ 0.04] compared with propensity-matched
patients enrolled in EUVAS trials.
Conclusions. This regimen is potentially superior to current
standards of care, and controlled studies are warranted to estab-
lish the utility of combination drug approaches in the treatment
of AAV.
Keywords: ANCA-associated vasculitis, cyclophosphamide,
granulomatosis with polyangiitis, microscopic polyangiitis,
rituximab
INTRODUCTION
The past decade has seen B-cell depletion therapy using rituxi-
mab become an established treatment strategy in anti-neutrophil
cytoplasm antibody (ANCA)-associated vasculitis (AAV), both
for remission induction and remission maintenance. Its use was
initially described as add-on therapy in cases refractory to con-
ventional treatment [1–3], based on experience in other autoim-
mune diseases. In 2010, two landmark randomized controlled
trials, the Rituximab for ANCA-associated Vasculitis (RAVE)
and Randomised Trial of Rituximab versus Cyclophosphamide
for ANCA-associated Renal Vasculitis (RITUXVAS) studies [4,
5], suggested that it was non-inferior to treatment with cyclo-
phosphamide for induction treatment in AAV. It was subse-
quently approved for this indication in 2011. Recent cohort
studies and one randomized controlled trial—MAINtenance of
remission using RITuximab in Systemic ANca-associated
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vasculitis (MAINRITSAN)—suggest that continued re-treatment
with rituximab is also effective in preventing relapse [6, 7].
Current international guidelines suggest that rituximab may
be considered an effective alternative to cyclophosphamide in
patients presenting with organ- or life-threatening disease,
including those with renal involvement [8, 9]. Controlled evidence
examining the role of rituximab/corticosteroid regimens in
patients with severe renal involvement in AAV, however, is lack-
ing and few studies have examined the combined use of cyclo-
phosphamide and rituximab. Retrospective analysis of a large
cohort of patients enrolled in the Glomerular Disease
Collaborative Network suggested that combined or sequential use
of cyclophosphamide and rituximab is safe and associated with a
longer time to relapse compared with rituximab treatment alone,
although the case mix in this study was heterogeneous and treat-
ment regimens non-standardized [10]. Prolonged remission after
an oral cyclophosphamide and rituximab–based induction regi-
men has been reported in a subset of patients who also received
maintenance therapy with scheduled rituximab redosing [6, 11],
providing further evidence that a combination approach is safe
andmay be associated with a decreased risk of relapse.
Since 2006 we have used the combination of rituximab and
low-dose intravenous cyclophosphamide, with oral corticoste-
roids, for remission induction in renal AAV. Our adoption of
this protocol predates the reports of RAVE and RITUXVAS
and our initial rationale was to use rituximab to allow a reduc-
tion in cumulative exposure to cyclophosphamide, an agent
proven to be effective in early disease control. In 2011 we pub-
lished our initial experience using this strategy (‘CycLowVas’)
in a cohort of 23 patients, in whom we observed high rates of
remission and prolonged relapse-free survival [12]. We now
report our extended experience using this regimen in a larger
cohort with long-term follow-up and compare outcomes with
patients treated with cyclophosphamide-based regimens in
European Vasculitis Study Group (EUVAS) trials. We confirm
high rates of clinical response and prolonged B-cell depletion
that was associated with low relapse rates and improved patient
and renal survival during long-term follow-up.
MATERIALS AND METHODS
This is a cohort study of patients with renal AAV treated since
2006 at the Hammersmith Hospital, London, UK, using our
previously published combination regimen [12]. This report
includes 22 patients described in our initial report, with an
extended period of follow-up, and an additional 44 cases who
have been treated since.
All consecutive patients were considered for treatment with
this protocol. Inclusion criteria were active AAV with renal
involvement, as defined by the presence of circulating ANCA
detected by indirect immunofluorescence (IIF) or antigen-
specific assay and either (i) biopsy-proven pauci-immune glo-
merulonephritis or (ii) active urinary sediment and abnormal
renal function in patients with evidence of glomerulonephritis
on former biopsy. Patients were assigned to myeloperoxidase
(MPO)-ANCA or proteinase 3 (PR3)-ANCA groups according
to antigen-specific testing. Two patients negative by antigen-
specific assay were positive for perinuclear ANCA by IIF, with-
out granulomatous features, and so were assigned to the MPO-
ANCA group.
Exclusion criteria included severe renal disease (serum crea-
tinine>500lmol/L or requirement for dialysis at initial presenta-
tion), diffuse alveolar haemorrhage, cerebral vasculitis or other
extrarenal manifestations requiring the addition of plasma
Table 1. Treatment protocol
Agent Dose
Cytotoxic therapy
Day 0 Rituximab 1 g
Cyclophosphamide i.v. 10 mg/kg (maximum 750 mg)
Week 2 Rituximab 1 g
Cyclophosphamide i.v. 10 mg/kg (max. 750 mg)
Weeks 4, 6, 8 and 10 Cyclophosphamide i.v. 500 mg  4
Corticosteroid taper
Week 1 Oral prednisolone 1 mg/kg/day (maximum 60 mg)
Week 2 25% reduction 45 mg
Week 3 33% reduction 30 mg
Week 4 33% reduction 20 mg
Week 6 25% reduction 15 mg
Week 12 Minimum 12.5 mg
Week 20 10 mg
Maintenance therapy
From Week 12 Azathioprine 1–2 mg/kg/day (adjusted for TPMT levels)
Mycophenolate mofetil (if intolerant) 1–2 g/day (targeted to trough levels of 1.2–2.4 mg/L)
Prophylactic therapy
PJP prophylaxis Co-trimoxazole 480 mg/day
Pentamidine nebulizer 300 mg/month (if intolerant)
Peptic ulcer prophylaxis Proton-pump inhibition
Bone prophylaxis Vitamin D and calcium supplementation
Latent TB prophylaxis (in those from high-risk areas) Isoniazid 150 mg/day and pyridoxine 50 mg/week
i.v., intravenous; TPMT, thiopurine methyltransferase enzyme activity; PJP, Pneumocystis jiroveci pneumonia; TB, tuberculosis.
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exchange, and<1-year follow-up. Patients with contra-indications
to cytotoxic therapy (malignancy, acute infection and chronic sup-
purative lung disease) were not included. Patients were followed
up until the last clinical visit prior to 31 December 2015.
The treatment protocol is summarized in Table 1. In brief,
the regimen combines two 1 g doses of rituximab, six intrave-
nous doses of cyclophosphamide 500–750 mg and an initial
oral prednisolone dose of 1mg/kg (maximum 60 mg) daily that
is rapidly tapered by Month 6 to 10mg/day maximum. In
patients who received intravenous corticosteroids prior to refer-
ral to our centre, a reduced initial oral corticosteroid dose was
permitted at the physician’s discretion. Corticosteroid taper
after 6 months was not protocolized and likewise at the physi-
cian’s discretion. Maintenance immunosuppression was com-
menced at 3 months (or earlier in patients who received shorter
courses of cytotoxic therapy) and recommended to continue for
at least 2 years.
Disease activity was scored using version 3 of the
Birmingham Vasculitis Activity Score (BVAS) [13]. Remission
was defined as a BVAS score of 0. At 6 months, patients with
persistent urinary abnormalities in the presence of improving
or stable excretory renal function and no extrarenal disease
activity were determined to have a BVAS score of 0. Renal biop-
sies were categorized according to the Berden classification
[14]. B-cell counts were determined by flow cytometry for
CD19þ cells at 3- to 6-month intervals and a threshold of 10
cells/lL was used to define B-cell depletion/repopulation.
ANCA was detected by IIF (Inova Diagnostics, San Diego, CA,
USA) or antigen specific assay (2006–2013: FIDIS Multiplex,
Theradiag, Marne-la-Vallee, France; 2013–2015: Immunocap250
CMIA, ThermoFisher Scientific, Waltham, MA, USA). The glo-
merular filtration rate (GFR) was estimated using the
Modification of Diet in Renal Disease calculation [15]. Relapse
was defined by an increase in disease activity requiring aug-
mented treatment. Major relapse included patients with recurrent
glomerulonephritis or respiratory tract involvement that required
re-treatment with cytotoxic agents. Minor relapses included con-
stitutional symptoms, arthralgia and ear, nose and throat (ENT)
symptoms that required a reintroduction or increase in dose of
oral corticosteroids/immunosuppression.
For unadjusted analysis, all data were regarded as non-
parametric and comparison between groups was by Fisher’s
exact test for categorical data and Mann–Whitney test for con-
tinuous variables. Survival functions and time-to-event analyses
were plotted as Kaplan–Meier curves and groups were com-
pared by log-rank test. ESRD- and relapse-free functions were
censored for death. B-cell count and ANCA levels were cen-
sored at the point of re-treatment with cytotoxic therapy.
Graphs were constructed and statistical analysis performed
using Prism 7.0 (GraphPad Software, La Jolla, CA, USA).
For case–control analysis, patients enrolled in previous
EUVAS trials [Cyclophosphamide vs Azathioprine during
Remission of Systemic Vasculitis (CYCAZAREM) [16],
Cyclophosphamide in Systemic Vasculitis (CYCLOPS) [17] and
Plasma Exchange for Renal Vasculitis (MEPEX) [18]] were iden-
tified in a ratio of 3:1 with our patient cohort and propensity
matched by age, baseline chronic kidney disease (CKD) staging
criteria and ANCA specificity. Cox proportional regression anal-
ysis was used to ascertain proportional hazard ratios (HRs) for
factors associated with categorical outcomes (death, progression
to ESRD, relapse). Covariates included age, sex, ANCA
specificity, entry eGFR, entry BVAS and dose of cyclophospha-
mide. Analysis was performed using SPSS version 23 (IBM,
Armonk, NY, USA).
This was a retrospective review meeting the criteria for a
service evaluation study and hence did not require approval
from a research ethics committee. All patients gave their con-
sent for treatment and received standard care according to our
accepted unit protocols.
RESULTS
Case identification
Between 2006 and 2014, 184 consecutive patients were
treated for new or relapsing renal AAV at our centre, all of
whom were considered for treatment with this protocol.
Excluded from this analysis are patients who had severe disease
manifestations requiring the addition of plasma exchange
(n¼ 49), those with ‘double-positive’ ANCA and anti-
glomerular basement membrane disease (n¼ 12), those who
had contraindications or declined to consent to a component of
therapy (n¼ 25) and those who were recruited to clinical trials
or other cohort studies (n¼ 30). Of the 68 patients treated, two
moved out of the centre in the first year of follow-up. The demo-
graphic features of the remaining 66 patients with at least 1-year
follow-up included in this analysis are summarized in Table 2.
The median duration of follow-up for the entire cohort was
56months [range 1–120].
Baseline disease features
The majority of patients [59/66 (89%)] were treated for de
novo presentations. All had renal involvement (median creati-
nine 205 lmol/L, eGFR 25mL/min; biopsy proven in all but
two cases). A spectrum of histological class of disease was
observed, although none had sclerotic-class disease. Extrarenal
manifestations were present in 59/66 (89%; median BVAS at
presentation 18.5). PR3-ANCA patients [33/66 (50%)] were
younger and had more extrarenal manifestations and higher
BVAS, with less evidence of chronic damage on biopsy than
MPO-ANCA patients, in keeping with previously reported clin-
icopathologic differences between these groups (Table 2).
Treatment received
All patients received rituximab 2 1 g. The median cumula-
tive dose of delivered cyclophosphamide was 3 g (range 1–5.5).
Thirteen patients (20%) received fewer than the protocolized
six doses of cyclophosphamide due to leucopenia, infection or
(in relapsing patents) concerns regarding prior cumulative
dose. One non-responding patient (discussed further below)
had an additional 4  500mg doses until remission was
achieved. Fourteen patients (22%) received pulsed intravenous
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methylprednisolone prior to referral. The median cumulative
dose of total oral and intravenous corticosteroids at 6 months
was 4.2 g (range 1.0–6.5).
At 6 months, 58/64 surviving patients (91%) were receiving
maintenance immunosuppression: 45/64 (70%) with azathio-
prine and 12/64 (19%) with mycophenolate mofetil (MMF).
One was converted to scheduled rituximab redosing due to
intolerance of both azathioprine and MMF. Six (9%) were not
receiving maintenance immunosuppression due to intolerance
or risk of infectious complications.
Early response
Sixty-two patients (94%) achieved remission by 6 months
(Figure 1A) and all but four were compliant with the
protocolized corticosteroid taper at this time point (Figure 1B).
In keeping with clinical response, there were rapid improve-
ments in serum C-reactive protein (CRP; Figure 1C) and creati-
nine (Figure 1D) by Month 3, which were sustained during the
first year of treatment. All patients achieved B-cell depletion
(<10 cells/lL) within 3 months (Figure 1E) and this was associ-
ated with a rapid decrease in ANCA titres during the first year
of treatment (Figure 1F).
Of the four patients who did not achieve remission by
Month 6, one required the addition of plasma exchange and
extended treatment with cyclophosphamide due to deteriorat-
ing renal function despite initial protocol treatment. One had
persistent ENT symptoms and required additional oral cortico-
steroid therapy; she subsequently achieved remission by 9
months. Two patients died in the first 6 months; one due to a
cerebrovascular accident at Month 1 and one due to multi-
organ failure secondary to chest sepsis at Month 5.
Long-term outcomes
Figure 2A and B describe long-term changes in eGFR and
renal survival, respectively. Four patients progressed to ESRD
during follow-up (at 3, 8, 37 and 69months). These patients
tended to be older [median 71 years (range 58–82)] and had
adverse indicators of renal outcome at presentation [median
creatinine 352 lmol/L (range 213–479) and median tubular
atrophy 25% (range 25–50)]. Three had mixed-class histology;
the remaining patient had crescentic-class disease.
Fifty-seven patients were alive at the last follow-up
(Figure 2B). Details of the nine deaths are summarized in
Table 3. The median time to death after presentation was 29
months (range 1–67) and the median age at death was 77 years
(range 57–88).
Figure 2E describes the duration of steroid exposure during
long-term follow-up. The median time to achieving corticoste-
roid dose5mg/day was 9.9months and the median dose of
oral corticosteroids at 1, 2 and 4 years was 5mg (IQR 5–7.5),
4mg (IQR 0–5) and 0mg (IQR 0–5), respectively. At Years 2
and 4, 85 and 79% of surviving patients, respectively, continued
onmaintenance immunosuppressive.
Relapse
At 1, 3 and 5 years, 100, 93 and 70% of surviving patients
were free from relapse, respectively. Of the patients, 0, 8 and
15% had major relapse at these time points, respectively
(Figure 2C). Of note, we did not observe a difference in relapse
rate between MPO-ANCA- and PR3-ANCA-positive patients
(P¼ 0.09; Figure 2D). At last follow-up, a total of 10 patients
had experienced a major relapse. The majority of these (70%)
occurred in patients who were positive for MPO-ANCA and all
were ANCA positive at the time of relapse. Ninety percent had
repopulated B cells (>10 cells/lL) and the majority (90%) were
on maintenance treatment. The median time to major relapse
was 39months (range 15–75).
Long-term B-cell and ANCA kinetics
We observed prolonged B-cell depletion in this cohort. At 6,
12, 18 and 24months, 97, 79, 63 and 57% of patients remained
B-cell deplete (<10 cells/lL), respectively (Figure 3A). In total,
Table 2. Demographic features and disease status at presentation
All MPO-ANCA PR3-ANCA P-value
Demographics
n (%) 66 (100) 33 (50) 33 (50)
Male:female, % 58:42 52:48 64:36 0.46
Age (years), median (range) 62 (17–84) 68 (17–84) 59 (19–81) 0.04
Comorbidities, %
Respiratory 21 30 12 0.13
Cardiac 12 15 9 0.71
Diabetes 12 15 9 0.71
Hypothyroidism 18 18 18 1.00
Disease status
De novo presentation, % 89 91 88
BVAS, median (range) 18.5 (12–31) 17 (12–31) 21 (12–29) <0.01
Creatinine (lmol/L), median (range) 205 (63–479) 213 (74–479) 180 (63–440) 0.56
eGFR (mL/min), median (range) 25 (8–86) 24 (8–71) 33 (8–90) 0.44
Biopsy class, % 0.65
Focal 24 21 27
Crescentic 33 30 33
Mixed 42 48 36
Tubular atrophy, % (range) 10 (0–50) 20 (10–50) 10 (0–40) 0.01
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64% of patients had repopulated B cells at the last follow-up,
with a median time to repopulation of 18months (range 1–99)
in those who did replete. ANCA-negative seroconversion
occurred in 86% of patients (Figure 3B and E) at a median time
of 4.4months (range 0.4–46.3). Of those patients who
achieved ANCA negativity, 60% had a subsequent return of
ANCA at a median of 15.0months (range 2.7–103.0). There
was a trend for earlier return of MPO-ANCA versus PR3-
ANCA (P¼ 0.07), which may have contributed to the unex-
pected similarity in relapse rates in these groups. Figures 2C
and D describe the incidence of relapse in patients who had
B-cell repopulation versus those who did not and in those
who had sustained ANCA negativity versus those who did
not, respectively. B-cell repletion and return of ANCA had a
poor positive predictive value for relapse (28 and 38%,
respectively) but they had a high negative predictive value
(100 and 91%, respectively). Figure 2F describes the relation-
ship of B-cell and ANCA kinetics to the incidence of relapse
for the entire cohort.
Adverse events
Table 3 details the adverse events seen during the entire
follow-up. Twenty patients (30%) had at least one Grade III
infection requiring intravenous antibiotic therapy or admission
to hospital during a total median follow-up of 56months. The
overall serious infection rate during long-term follow-up was
1.24 per 10 patient-years. The infection rate tended to be lower
in patients who repopulated B cells within 12months (0.95 per
10 patient-years) compared with those who repopulated within
or after 24months (1.33 and 1.17 per 10 patient-years, respec-
tively). Four patients developed persistent hypogammaglobuli-
naemia, two of whom required treatment with intravenous
immunoglobulin. We did not observe late-onset neutropenia.
A small number of non-skin cancers (n¼ 3) and non-
melanoma skin cancers (n¼ 3) were detected.
Case–control study with EUVAS trial patients
Table 4 describes the baseline features of our cohort
(‘CycLowVas’) compared with propensity-matched control
FIGURE 1: Early disease response at 6 and 12 months. (A) BVAS at 0 and 6 months. (B) Oral prednisolone dose (mg/day) during the ﬁrst
year of therapy. Fourteen patients received pulsed intravenous methylprednisolone prior to referral to our centre and in these cases the initial
dose of oral prednisolone was reduced. (C) Sequential serum CRP (mg/L). D Serum creatinine (lmol/L). (E) Peripheral B lymphocyte count
(cells/lL). (F) ANCA titres as determined by antigen speciﬁc assay (1F) at 3, 6 and 12 months. Box and whisker plots represent median (IQR)
and range measurements.
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patients enrolled in previous EUVAS studies. The patients were
well matched for age, ANCA specificity, BVAS and CKD stage
at presentation. Rates of remission and changes in eGFR at
6 months were comparable between groups and, in unadjusted
analyses, the proportion of patients encountering relapse was
not statistically different for the two patient cohorts (21% versus
30.8%; P¼ 0.18). However, PR3-ANCA-positive patients
treated with the CycLowVas regimen were significantly less
likely to relapse (15% versus 43%; P¼ 0.008). In multivariable
analyses, treatment with the CycLowVas regimen was associ-
ated with a reduced risk of death {HR 0.29 [95% confidence
interval (CI) 0.125–0.675], P¼ 0.004}, progression to ESRD
[HR 0.20 (95% CI 0.06–0.65), P¼ 0.007] and relapse [HR 0.49
(95% CI 0.25–0.97), P¼ 0.04]. Figure 4 shows the Cox propor-
tional hazards regression curves describing the long-term risk
of death, ESRD and relapse.
DISCUSSION
This combined treatment regimen provided early disease control
in renal AAV and was effective in 94% of patients at 6 months.
Long-term patient and renal survival were favourable and
relapse rates were lower than expected compared with previously
published cohorts treated with purely cyclophosphamide-based
regimens.
There are limited data describing the use of rituximab-based
therapy in patients with severe renal involvement in AAV.
Small case series suggest that rituximab may be effective in this
context, although cases were heterogeneous [19, 20]. In the larg-
est controlled study to date, the RAVE trial, only 50% of
patients had renal involvement. While post hoc analysis sug-
gested that outcomes of patients with renal involvement were
comparable in the subgroups treated with rituximab and cyclo-
phosphamide, it is notable that excretory renal function at entry
was relatively well preserved in these patients, with eGFRs in
the range of 40–60mL/min [21]. Although patients in the
RITUXVAS study had more severe renal involvement, with an
average eGFR of 18mL/min, patients in the rituximab treat-
ment arm also received two intravenous doses of cyclophospha-
mide, with the stated aim of ensuring early disease control and
to prevent the potential induction of human anti-chimeric anti-
bodies (EUDRACT 2005-003610-15) [5]. It has been suggested
that cyclophosphamide may have effects beyond B-cell deple-
tion that are of early benefit in renal disease, such as elimination
of pathogenic T cells or intrarenal macrophages [22]. We agree
with this rationale and believe that cyclophosphamide may be a
beneficial component of initial treatment for patients with renal
impairment secondary to severe pauci-immune glomerulo-
nephritis to ensure rapid suppression of renal inflammation
and prevention of long-term damage.
FIGURE 2: Long-term outcomes during 5-year follow-up. (A) eGRF (mL/min) at annual intervals during 5-year follow-up. Data censored at
point of progression to end-stage renal disease for four patients. Unadjusted Kaplan–Meier survival functions describing (B) overall and
ESRD-free survival (the latter censored for death) and relapse-free survival censored for death in (C) MPO-ANCA- and (D) PR3-ANCA-posi-
tive patients during the 5-year follow-up. (E) Long-term steroid exposure in the cohort during the 5-year follow-up (censored for relapse). Box
and whisker plots represent median (IQR) and range measurements.
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Previous studies have shown that an increased dose or longer
duration of cyclophosphamide treatment is associated with lower
rates of relapse [23, 24], with the corollary of increased rates
of adverse events such as infection and malignancy [25–28].
Our experience suggests that the addition of 2 1 g doses of rit-
uximab to the induction regimen permits reduction in the cyclo-
phosphamide dose required to achieve prolonged remission. Our
patients received 3 g cyclophosphamide, compared with 8.2 and
15.9 g in the pulsed intravenous and daily oral arms, respectively,
of the CYCLOPS study [29], and showed sustained disease-free
remission, with relapse rates that were comparable between PR3-
and MPO-ANCA-positive cases. These observations are in keep-
ing with other findings that suggest rituximabmay be particularly
effective in preventing relapsing disease and in those who are
PR3-ANCA positive. In the RAVE study, PR3-ANCA-positive
patients had better initial response to rituximab versus cyclophos-
phamide [30]. In addition, subgroup analysis found that rituxi-
mab was particularly beneficial in patients who were treated for
relapsing disease, and longer term follow-up implied that a single
treatment with rituximab was non-inferior to conventional con-
tinuous oral immunosuppression for prevention of relapse at 18
months [31].
We observed prolonged peripheral B-cell depletion in our
cohort, which we believe contributed to the reduced risk of
relapse and improved long-term outcomes. At 2 years, 50% of
patients remained B-cell deplete without further cytotoxic
therapy. This is in contrast to the RAVE and RITUXVAS stud-
ies, in which the majority of rituximab-treated patients recon-
stituted B by 12 months [31, 32], suggesting a synergistic effect
whereby cyclophosphamide and rituximab potentiate their
respective effects on B-cell elimination. Anti-CD20 monoclonal
antibody treatment has been shown to sensitize lymphoma cell
lines to cyclophosphamide-mediated cytotoxicity in vitro [33],
and multitarget therapy is a well-established strategy in the
oncology clinic. Sustained B-cell depletion with repeated rituxi-
mab treatment has been associated with a decreased risk of
relapse in other studies [6, 7], and our experience suggests that
this may effectively be achieved with combination therapy at
induction.
B-cell depletion was associated with high rates of serocon-
version to ANCA negativity (86%), which occurred in the first 6
months of therapy for most patients, an observation that has
been associated with a reduced relapse risk in other cohorts
[34]. It is striking that, as a cohort, B-cell repopulation preceded
the recurrence of ANCA, which in turn preceded the develop-
ment of relapse (Figure 3F), and that 90% of major relapses
occurred in patients who were both B-cell replete and ANCA
positive. This is in keeping with recent evidence that ANCA
Table 3. Adverse events and deaths
Infectious adverse events
At least one infection requiring i.v. antibiotics or admission 20
Zoster 5
CMV viraemia 2
Aspergillus 1
PJP None
PML None
Hepatitis reactivation None
Non-infectious adverse events
New diabetes 7
Osteoporosis or bone fracture 5
Venous thromboembolism 3
Cardiac events 3
Persistent hypo-IgG 4
Late-onset neutropenia None
Cancer 6
SCC 2
BCC 1
Breast 1
Lung 1
Prostate 1
Deaths
Case Age (years) Time point (months) Cause
1 79 1 Cerebrovascular disease
2 70 5 Chest sepsis
3 57 15 Unknown
4 82 19 Unknown
5 63 29 Lung cancer
6 76 39 Sudden cardiac
7 88 39 Sudden cardiac
8 77 40 Chest sepsis (chronic airways disease)
9 86 67 Unknown
i.v., intravenous; CMV, cytomegalovirus; PJP, Pneumocystis jiroveci pneumonia; PML, progressive multifocal leucoencephalopathy; IgG, immunoglobulin G; SCC, squamous cell carci-
noma; BCC, basal cell carcinoma.
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may be a useful predictor of relapse in patients with renal
involvement [35]; however, because the overall relapse rate was
low, we were unable to identify B-cell or ANCA parameters
that were positively predictive of recurrence. Reassuringly, pro-
longed B-cell depletion was not associated with an unexpectedly
high incidence of adverse events. Rates of infection and hypo-
gammaglobulinamia were comparable with other studies,
including a recent analysis of patients multiply re-treated with
rituximab [11]. Nor did we observe an excess of malignancies,
in keeping with a recent retrospective analysis that suggested
patients with AAV treated with rituximab have a comparable
risk of malignancy with the general population [36].
While this protocol used combination cytotoxic therapy, it
was relatively corticosteroid sparing. Patients did not receive
intravenous corticosteroids at our centre and oral corticoste-
roids were rapidly tapered during the first month, giving a
median total dose of 4.2 g by 6 months. This is in contrast to the
CYCLOPS study, where an average corticosteroid dose of 7.5 g
was administered during induction, and the RAVE study, where
high-dose intravenous corticosteroids were employed and ini-
tial doses of oral prednisolone of 40–60mg were maintained for
the first month of therapy (giving a cumulative total oral and
intravenous dose approaching 6 g). Similarly, our regimen used
less cumulative corticosteroids than most reported studies of
induction therapy in AAV (Supplementary data, Table S1 and
reference [37]). It is possible that the avoidance of high-dose
corticosteroid exposure, and the associated toxicity [38, 39], may
have allowed the safe combination of two cytotoxic therapies
FIGURE 3: B-cell and ANCA kinetics and their relationship to relapse during the 5-year follow-up. Kaplan–Meier functions describing (A)
the proportion of patients who remained free of peripheral B cells (<10 cells/uL) and (B) the time taken to achieve ANCA-negative testing as
determined by antigen-speciﬁc assay during the 5-year follow-up. Kaplan–Meier functions describing the incidence of ﬁrst major or minor
relapse in (C) patients who had a return of peripheral B cells (>10 cells/uL) versus those who did not and (D) patients who remained ANCA
negative versus those who had a return of ANCA in those patients who became ANCA negative after initial treatment during the 5-year fol-
low-up. (E) Heatmap describing sequential ANCA measurements in the 62 patients who survived beyond 6 months and who were ANCA pos-
itive by antigen-speciﬁc assay during long-term follow-up. The occurrence of major relapse is indicated by ﬁlled circles. (F) Composite
Kaplan–Meier curve describing the sequence of B-cell repopulation, return of circulating ANCA and the occurrence of relapse for the entire
cohort over the 5-year follow-up. The red plot shows the time to achieve ANCA-negative testing, the blue plot describes the time for return of
peripheral B cells, the grey plot describes the time for return of circulating ANCA in those patients who had previously achieved ANCA-nega-
tive testing and the black plot describes the time to the ﬁrst minor or major relapse.
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without encountering an excess of infectious complications.
Curtailment of corticosteroid therapy has been associated with
an increased risk of relapse using conventional treatment regi-
mens [40], although this risk may likewise be outweighed byTa
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FIGURE 4: Case–control analysis with propensity-matched patients
from EUVAS trials. Cox proportional hazards regression models.
(A) The adjusted all-cause mortality, (B) ESRD and (C) relapse risk
between the EUVAS cohort and combined treatment (‘CycLowVas’)
cohort. The covariates in the analysis include age, sex, ANCA specif-
icity, entry eGFR, entry BVAS and dose of cyclophosphamide.
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the benefit accrued from combination cytotoxic therapy for
long-term disease control, and we suggest that this combined
regimen may provide the basis for early corticosteroid with-
drawal in AAV. Results from the ongoing PEXIVAS (Plasma
Exchange and Glucocorticoids for Treatment of Anti-
Neutrophil Cytoplasm Antibody-Associated Vasculitis) study,
which includes randomization to either standard (estimated
4.2 g) or reduced dose (2.3 g) oral corticosteroids, may provide
further information on the efficacy and safety of such an
approach [41].
A limitation of our case–control analysis is the use of a his-
torical group of patients enrolled to EUVAS studies during a
time period that predates our cohort’s recruitment. It is
recognized that survival in AAV has improved over recent dec-
ades [42–44], such that factors other than drug protocol may
have contributed to the improved outcomes in our more
recently treated cohort. It is notable, however, that the largest of
these studies did not observe a change in relapse frequency over
time [44], indicating that the lower relapse rate observed in our
cohort may remain significant. A further limitation of our study
is that the use of maintenance therapy was not standardized
and this may, along with the combination induction regimen,
have contributed to the long-term outcomes we described. The
recently published findings of the EUVAS coordinated REMAIN
(Randomised Trial of Prolonged Remission-Maintenance
Therapy in Systemic Vasculitis) study for example confirm that
prolonged maintenance treatment is associated with reduced risk
of relapse [45], although the applicability of its results in the
rituximab-based induction era may be limited. In addition, we
have not examined the efficacy of this regimen in patients pre-
senting with severe disease manifestations requiring plasma
exchange, such as those presenting with renal failure requiring
dialysis or diffuse alveolar haemorrhage, and our cohort included
a low proportion of patients with relapsing disease at enrolment.
Finally, as a clinical cohort study, we were unable to examine the
B-cell phenotype and kinetics with the granularity described in
recent mechanistic work, and it would be of interest to define
these features in more detail in the future [46, 47].
CONCLUSION
This report has the intrinsic limitations of a single-centre,
uncontrolled, open-label study, although its strengths include a
highly standardized cytotoxic treatment regimen, long-term
follow-up and a formal case–control comparison with pub-
lished trials suggesting favourable outcomes. We propose that
prospective studies are desirable to compare the use of this regi-
men, and other B-cell-depleting strategies [48], with current
standard treatment protocols (and in particular to purely
rituximab-based induction and maintenance strategies and in
patients with relapsing disease) and to establish if this regimen
may provide the basis for further corticosteroid avoidance in
the management of renal AAV.
SUPPLEMENTARY DATA
Supplementary data are available at ndt online.
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